ArticleJournal of asthma and allergy2011
Update on optimal use of omalizumab in management of asthma.
Article in Journal of asthma and allergy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Omalizumab for asthma in adults and children.The Cochrane database of systematic reviews · 2014Pooled it
- A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma.Respiratory research · 2016Trial
- Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease.Clinical and translational allergy · 2026Review
- The identification of biomarkers for response to omalizumab in adult asthma based on untargeted metabolomic analysis.Medicine · 2026Article
- Off-label applications of omalizumab: Current insights and perspectives.The World Allergy Organization journal · 2025Review
- The Mechanisms of Immunoglobulin E Sensitizations in Atopic Dermatitis.Immunology and allergy clinics of North America · 2025Review
- Cost-utility analysis of omalizumab for the treatment of chronic spontaneous urticaria in China.Cost effectiveness and resource allocation : C/E · 2025Article
- Article
- Japanese Patients with Severe Asthma Identified as Responders to Omalizumab Treatment at 2 Years Based on the GETE Score Continued Treatment for an Extended Period.Journal of asthma and allergy · 2024Article
- Switching to Dupilumab from Other Biologics without a Treatment Interval in Patients with Severe Asthma: A Multi-Center Retrospective Study.Journal of clinical medicine · 2023Article
- Life-threatening anaphylaxis in children with cow's milk allergy during oral immunotherapy and after treatment failure.Immunity, inflammation and disease · 2022Article
- Regulation of Trafficking and Signaling of the High Affinity IgE Receptor by FcεRIβ and the Potential Impact of FcεRIβ Splicing in Allergic Inflammation.International journal of molecular sciences · 2022Review
- Asthma biologics: Comparing trial designs, patient cohorts and study results.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2020Review
- SLAP Is a Negative Regulator of FcεRI Receptor-Mediated Signaling and Allergic Response.Frontiers in immunology · 2019Article
- Targeted therapy in severe asthma today: focus on immunoglobulin E.Drug design, development and therapy · 2017Review
- Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience.BMC pulmonary medicine · 2016Observational
- IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.Journal of immunology research · 2016Review
- Functional relevance of NLRP3 inflammasome-mediated interleukin (IL)-1β during acute allergic airway inflammation.Clinical and experimental immunology · 2014Article
- Update on anticytokine treatment for asthma.BioMed research international · 2013Review
- IgE and mast cells in allergic disease.Nature medicine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing interaction with cellular IgE receptors. Omalizumab is also capable of downregulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both blood and induced sputum. The clinical effects of omalizumab include improvements in respiratory symptoms and quality of life, paralleled by a reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Omalizumab is relatively well-tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent allergic asthma inadequately controlled by high doses of standard inhaled treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.